{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:26:35Z","timestamp":1792128395586,"version":"4.4.0"},"reference-count":114,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secondary acute myeloid leukemias (AMLs) evolving from an antecedent myeloproliferative neoplasm (MPN) are characterized by a unique set of cytogenetic and molecular features distinct from de novo AML. Given the high frequency of poor-risk cytogenetic and molecular features, malignant clones are frequently insensitive to traditional AML chemotherapeutic agents. Allogeneic stem cell transplant, the only treatment modality shown to have any beneficial long-term outcome, is often not possible given the advanced age of patients at time of diagnosis and frequent presence of competing comorbidities. Even in this setting, relapse rates remain high. As a result, outcomes are generally poor and there remains a significant unmet need for novel therapeutic strategies. Although advances in cancer genomics have dramatically enhanced our understanding of the molecular events governing clonal evolution in MPNs, the cell-intrinsic and -extrinsic mechanisms driving leukemic transformation at this level remain poorly understood. Here, we review known risk factors for the development of leukemic transformation in MPNs, recent progress made in our understanding of the molecular features associated with leukemic transformation, current treatment strategies, and emerging therapeutic options for this high-risk myeloid malignancy.<\/jats:p>","DOI":"10.1182\/blood.2019000943","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T20:54:43Z","timestamp":1589921683000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":157,"title":["Leukemia secondary to myeloproliferative neoplasms"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-4220","authenticated-orcid":false,"given":"Andrew J.","family":"Dunbar","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine,"},{"name":"Center for Hematologic Malignancies,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-6368","authenticated-orcid":false,"given":"Raajit K.","family":"Rampal","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine,"},{"name":"Center for Hematologic Malignancies,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-1905","authenticated-orcid":false,"given":"Ross","family":"Levine","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine,"},{"name":"Center for Hematologic Malignancies,"},{"name":"Human Oncology and Pathogenesis Program, and"},{"name":"Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2020070211295006400_B1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"2020070211295006400_B2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J Transl Med"},{"issue":"6","key":"2020070211295006400_B3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"16","key":"2020070211295006400_B4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2020070211295006400_B5","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020070211295006400_B6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"9","key":"2020070211295006400_B7","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2020070211295006400_B8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2020070211295006400_B9","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"2020070211295006400_B10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ccr3.1264","article-title":"Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure","volume":"6","author":"Alhuraiji","year":"2017","journal-title":"Clin Case Rep"},{"issue":"8","key":"2020070211295006400_B11","first-page":"FC13","article-title":"Diagnostic value of bone marrow aspiration and biopsy in routine hematology practice","volume":"8","author":"Kaur","year":"2014","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"2020070211295006400_B12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","article-title":"AML transformation in 56 patients with Ph- MPD in two well defined populations","volume":"82","author":"Abdulkarim","year":"2009","journal-title":"Eur J Haematol"},{"issue":"50","key":"2020070211295006400_B13","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"2020070211295006400_B14","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020070211295006400_B15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am J Hematol"},{"issue":"31","key":"2020070211295006400_B16","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020070211295006400_B17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/jjco\/hyq097","article-title":"Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8","volume":"40","author":"Koh","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"2020070211295006400_B18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2020070211295006400_B19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bmt.2014.31","article-title":"Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Fran\u00e7aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"49","author":"Cahu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2020070211295006400_B20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"2020070211295006400_B21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020070211295006400_B22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2020070211295006400_B23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020070211295006400_B24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020070211295006400_B25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"14","key":"2020070211295006400_B26","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020070211295006400_B27","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk Res"},{"issue":"12","key":"2020070211295006400_B28","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"2020070211295006400_B29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","article-title":"Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence","volume":"150","author":"Passamonti","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2020070211295006400_B30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.21391","article-title":"Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"},{"issue":"7","key":"2020070211295006400_B31","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2020070211295006400_B32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"1","key":"2020070211295006400_B33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"issue":"29","key":"2020070211295006400_B34","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020070211295006400_B35","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020070211295006400_B36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clml.2013.01.001","article-title":"Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia","volume":"13","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2020070211295006400_B37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"2020070211295006400_B38","unstructured":"National Comprehensive Cancer Network\n          . Myeloproliferative neoplasms (version 2.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed 3 January 2020."},{"issue":"2","key":"2020070211295006400_B39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"33","key":"2020070211295006400_B40","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020070211295006400_B41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"2020070211295006400_B42","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2020070211295006400_B43","first-page":"200","article-title":"Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction","volume":"7","author":"Barosi","year":"1993","journal-title":"Leukemia"},{"issue":"10","key":"2020070211295006400_B44","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2020070211295006400_B45","first-page":"359","article-title":"Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases","volume":"36","author":"Lafaye","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"issue":"7","key":"2020070211295006400_B46","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"10","key":"2020070211295006400_B47","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020070211295006400_B48","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2020070211295006400_B49","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/leu.2008.218","article-title":"Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)","volume":"22","author":"Reilly","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2020070211295006400_B50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"issue":"3","key":"2020070211295006400_B51","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"2020070211295006400_B52","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.21358","article-title":"Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia","volume":"104","author":"Tefferi","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"2020070211295006400_B53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(02)00678-7","article-title":"Karyotypic abnormalities in myelofibrosis following polycythemia vera","volume":"140","author":"Andrieux","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2020070211295006400_B54","first-page":"224","article-title":"Karyotype and molecular cytogenetic studies in polycythemia vera","volume":"4","author":"Andrieux","year":"2005","journal-title":"Curr Hematol Rep"},{"issue":"1","key":"2020070211295006400_B55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"2020070211295006400_B56","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2020070211295006400_B57","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020070211295006400_B58","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2020070211295006400_B59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"14","key":"2020070211295006400_B60","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2020070211295006400_B61","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2020070211295006400_B62","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2020070211295006400_B63","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2020070211295006400_B64","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2020070211295006400_B65","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"2020070211295006400_B66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"20","key":"2020070211295006400_B67","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020070211295006400_B68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"2020070211295006400_B69","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2020070211295006400_B70","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2020070211295006400_B71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"issue":"25","key":"2020070211295006400_B72","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2009-06-223982","article-title":"AML1\/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2020070211295006400_B73","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2020070211295006400_B74","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020070211295006400_B75","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2020070211295006400_B76","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2008-07-167056","article-title":"Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F","volume":"113","author":"Schaub","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2020070211295006400_B77","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol Cell"},{"issue":"7","key":"2020070211295006400_B78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"2020070211295006400_B79","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020070211295006400_B80","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s11899-018-0491-5","article-title":"Leukemic transformation of myeloproliferative neoplasms: therapeutic and genomic considerations","volume":"13","author":"Li","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2020070211295006400_B81","doi-asserted-by":"crossref","first-page":"14.40.1","DOI":"10.1002\/cpph.23","article-title":"Overview of transgenic mouse models of myeloproliferative neoplasms (MPNs)","volume":"77","author":"Dunbar","year":"2017","journal-title":"Curr Protoc Pharmacol"},{"issue":"1","key":"2020070211295006400_B82","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2020070211295006400_B83","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"14","key":"2020070211295006400_B84","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020070211295006400_B85","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"2020070211295006400_B86","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/onc.2016.478","article-title":"Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera","volume":"36","author":"Tsuruta-Kishino","year":"2017","journal-title":"Oncogene"},{"issue":"9","key":"2020070211295006400_B87","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk Res"},{"issue":"9","key":"2020070211295006400_B88","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk Res"},{"issue":"2","key":"2020070211295006400_B89","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2020070211295006400_B90","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bbmt.2016.09.017","article-title":"Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by Philadelphia chromosome-negative myeloproliferative neoplasms: a nationwide survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation","volume":"22","author":"Takagi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020070211295006400_B91","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2020070211295006400_B92","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood.V128.22.1940.1940","article-title":"Survival outcome of patients with acute myeloid leukemia transformed from myeloproliferative neoplasms [abstract]","volume":"128","author":"Chihara","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020070211295006400_B93","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.21297","article-title":"Leukemic transformation of polycythemia vera: a single center study of 23 patients","volume":"104","author":"Passamonti","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"2020070211295006400_B94","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.leukres.2015.03.001","article-title":"Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN","volume":"39","author":"Andriani","year":"2015","journal-title":"Leuk Res"},{"issue":"3","key":"2020070211295006400_B95","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.0007-1048.2001.03319.x","article-title":"Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation","volume":"116","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"issue":"9","key":"2020070211295006400_B96","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"issue":"20","key":"2020070211295006400_B97","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2020070211295006400_B98","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","article-title":"A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2020070211295006400_B99","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2020070211295006400_B100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020070211295006400_B101","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2020070211295006400_B102","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2020070211295006400_B103","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"2020070211295006400_B104","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1182\/blood-2019-122380","article-title":"Outcomes of IDH-mutated advanced phase Ph-negative myeloproliferative neoplasms treated with IDH inhibitors [abstract]","volume":"134","author":"Cahill","year":"2019","journal-title":"Blood"},{"key":"2020070211295006400_B105","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"OncoTargets Ther"},{"issue":"3","key":"2020070211295006400_B106","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020070211295006400_B107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms [published correction appears in Cancer Cell. 2018;33(4):785-787]","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"2020070211295006400_B108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020070211295006400_B109","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"26","key":"2020070211295006400_B110","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders","volume":"359","author":"Zhao","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"2020070211295006400_B111","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"429","key":"2020070211295006400_B112","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"issue":"12","key":"2020070211295006400_B113","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2020070211295006400_B114","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/1\/61\/1747530\/bloodbld2019000943c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/1\/61\/1747530\/bloodbld2019000943c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T11:30:45Z","timestamp":1593689445000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/1\/61\/456028\/Leukemia-secondary-to-myeloproliferative-neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000943","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}